Does Systemic Isotretinoin Treatment Constitute a Predisposition to Allergic Sensitization?

Basit Öğe Kaydı
dc.authorscopusid56811496900
dc.authorscopusid56134262800
dc.authorscopusid6604070029
dc.contributor.authorCenk H.
dc.contributor.authorKapicioglu Y.
dc.contributor.authorYologlu S.
dc.date.accessioned2024-08-04T20:02:34Z
dc.date.available2024-08-04T20:02:34Z
dc.date.issued2021
dc.departmentİnönü Üniversitesien_US
dc.description.abstract13-cis-retinoic acid (13-cRA) is a safe treatment for severe acne, as it has immunomodulatory effects such as enhancing the antigen-presenting activity of epidermal Langerhans cells (LCs) and T-cell activity. The aim of this study was to prospectively show the alteration of sensitization and irritation reactions in acne patients undergoing 13-cRA therapy. This cross-sectional descriptive study consisted of 65 severe to refractory acne patients. The standard thin-layer rapid-use epicutaneous test (T.R.U.E. test) was used to screen sensitization and irritation reactions before and after 3-month 13-cRA treatment. Patch test results after 13-cRA therapy revealed an increase in newly formed sensitization and irritation reactions. Sensitization rate was significantly higher (43.1%) in the second patch test, when compared with the first patch test results (27.7%; P = 0.002). No statistical difference was found in irritation rates. In this study, the sensitization rate was higher after treatment, which could be attributed to the greater antigen penetration due to the disrupted barrier and/or the upregulation of antigen-presenting activity in LC. This would cause a more prominent immune reaction to antigens. Based on these findings, we suggest that 13-cRA may have a sensitization effect, and physicians should be aware of this complication due to 13-cRA treatment. (SKINmed. 2021;19:-0).en_US
dc.identifier.endpage34en_US
dc.identifier.issn1751-7125
dc.identifier.issue1en_US
dc.identifier.pmid33658110en_US
dc.identifier.scopus2-s2.0-85102483311en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage28en_US
dc.identifier.urihttps://hdl.handle.net/11616/91793
dc.identifier.volume19en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherNLM (Medline)en_US
dc.relation.ispartofSkinmeden_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectantigenen_US
dc.subjectdermatological agenten_US
dc.subjectisotretinoinen_US
dc.subjectacne vulgarisen_US
dc.subjectadolescenten_US
dc.subjectantigen presentationen_US
dc.subjectcross-sectional studyen_US
dc.subjectfemaleen_US
dc.subjecthumanen_US
dc.subjecthypersensitivityen_US
dc.subjectimmunologyen_US
dc.subjectLangerhans cellen_US
dc.subjectmaleen_US
dc.subjectpatch testen_US
dc.subjectprospective studyen_US
dc.subjectyoung adulten_US
dc.subjectAcne Vulgarisen_US
dc.subjectAdolescenten_US
dc.subjectAntigen Presentationen_US
dc.subjectAntigensen_US
dc.subjectCross-Sectional Studiesen_US
dc.subjectDermatologic Agentsen_US
dc.subjectFemaleen_US
dc.subjectHumansen_US
dc.subjectHypersensitivityen_US
dc.subjectIsotretinoinen_US
dc.subjectLangerhans Cellsen_US
dc.subjectMaleen_US
dc.subjectPatch Testsen_US
dc.subjectProspective Studiesen_US
dc.subjectYoung Adulten_US
dc.titleDoes Systemic Isotretinoin Treatment Constitute a Predisposition to Allergic Sensitization?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu